As per the research report, the size of the Europe PEGylated Proteins Market is valued at USD 208.56 million in 2019 and estimated to be growing at a CAGR of 10.20%, to reach USD 338.95 million by 2024. The market is showing great potential in the forecast period, i.e. till 2019-2024.
PEGylation is a process of attachment of covalent or non-covalent bond of PolyEthylene Glucol (PEG) polymer chains to molecules and macrostructures, like protein in case of PEGylation of proteins. PEGylated Protein has become very important because the PEGylation of proteins helps to protect protein against enzymatic dehydration and it also increases the half-life of drugs.
Increasing R&D investments in pharmaceuticals and healthcare sectors in this region because of high awareness of people regarding health-related issues, high risk of diseases, increase in adoption of protein-based drugs over non-protein based drugs and increased half-life of drugs due to PEGylation are the major driving factors of this market. On the other hand, the unpredictable accumulation of high molecular weight compounds in the liver might lead to inclusion bodies with no known consequences. Furthermore, the chain length of these compounds can change which might lead to unexpected clearance times in vivo. These concerning matters are challenging this market.
This research report segmented and sub-segmented into the following categories:
In Europe, Germany leads the PEGylated Proteins Market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about health and pharmacy, financial strength to procure expensive medicines and favorable reimbursement policies.
Key players operating in the Europe PEGylated Proteins Market profiled in this report are Laysan Bio, Ltd., Iris Biotech GmbH, Biomatrik Inc., Quanta BioDesign Ltd., Cealares GmbH, Creative PEGworks, Jenkem Technology USA Inc., NOF Corporation, Thermo Fisher Scientific Inc., and Merck Millipore.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Protein Type
5.1.1 Introduction
5.1.2 Interferons
5.1.3 Erythropoietin
5.1.4 mAbs
5.1.5 Y-o-Y Growth Analysis, By Protein Type
5.1.6 Market Attractiveness Analysis, By Protein Type
5.1.7 Market Share Analysis, By Protein Type
5.2 Consumables
5.2.1 Introduction
5.2.2 Reagents
5.2.3 PEGylation Kits
5.2.4 Y-o-Y Growth Analysis, By Consumables
5.2.5 Market Attractiveness Analysis, By Consumables
5.2.6 Market Share Analysis, By Consumables
5.3 Application
5.3.1 Introduction
5.3.2 Chronic Kidney Diseases
5.3.3 Cancer Treatment
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 End-Users
5.4.1 Introduction
5.4.2 Pharmaceuticals & Biotechnology Companies
5.4.3 CROs
5.4.4 Academic Research Institutes
5.4.5 Y-o-Y Growth Analysis, By End-Users
5.4.6 Market Attractiveness Analysis, By End-Users
5.4.7 Market Share Analysis, By End-Users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Protein Type
6.1.3.3 By Consumables
6.1.3.4 By Application
6.1.3.5 By End-Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Protein Type
6.1.4.3 By Consumables
6.1.4.4 By Application
6.1.4.5 By End-Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Protein Type
6.1.5.3 By Consumables
6.1.5.4 By Application
6.1.5.5 By End-Users
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Laysan Bio Ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Iris Biotech GmbH
8.3 Biomatrik Inc.
8.4 Quanta BioDesign Ltd.
8.5 Cealares GmbH
8.6 Creative PEGworks
8.7 Jenkem Technology USA Inc.
8.8 NOF Corporation
8.9 Thermo Fisher Scientific Inc.
8.10 Merck Millipore
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
